Information Provided By:
Fly News Breaks for March 24, 2016
BAYRY, REGN
Mar 24, 2016 | 10:48 EDT
After Regeneron (RGEN) and Bayer (BAYRY) announced they are partnering to co-formulate EYLEA + anti-Ang2 antibody nesvacumab, Piper Jaffray analyst Edward Tenthoff said the continued cooperation of the two companies is key to Regeneron maintaining its lead in ophthalmology. Tenthoff keeps a Neutral rating on Regeneron, noting that the company has guided for only 20% EYLEA sales growth this year and that Praluent's launch has been even slower than expected.
News For REGN;BAYRY From the Last 2 Days
REGN
REGN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.